Abstract:Introduction: C-type lectin domain family 11 member A (CLEC11A) was characterized as a growth factor that mainly regulates hematopoietic function and differentiation of bone cells. However, the involvement of CLEC11A in gastric cancer (GC) is not well understood. Methods: Transcriptomic data and clinical information pertaining to GC were obtained and analyzed from publicly available databases. The relationships between CLEC11A and prognoses, genetic alterations, tumor microenvironment (TME), and therapeutic responses in GC patients were analyzed by bioinformatics methods. A CLEC11A-derived immune signature was developed and validated, and its mutational landscapes, immunological characteristics as well as drug sensitivities were explored. A nomogram was established by combining CLEC11A-derived immune signature and clinical factors. The expression and carcinogenic effects of CLEC11A in GC were verified by qRT−PCR, cell migration, invasion, cell cycle analysis, and in vivo model analysis. Myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), M2 macrophages, and T cells in tumor samples extracted from mice were analyzed utilizing flow cytometry analysis. Results: CLEC11A was over-expressed in GC, and the elevated CLEC11A expression indicated an unfavorable prognosis in GC patients. CLEC11A was involved in genomic alterations and associated with the TME in GC. Moreover, elevated CLEC11A was found to reduce the benefit of immunotherapy according to immunophenoscore (IPS) and the tumor immune dysfunction, exclusion (TIDE). After validation, the CLEC11A-derived immune signature demonstrated a consistent ability to predict the survival outcomes in GC patients. A nomogram that quantifies survival probability was constructed to improve the accuracy of prognosis prediction in GC patients. Using shRNA to suppress the expression of CLEC11A led to significant inhibitions of cell cycle progression, migration, and invasion, as well as a marked reduction of in vivo tumor growth. Moreover, the flow cytometry assay showed that the knock-down of CLEC11A increased the infiltration of cytotoxic CD8+ T cells and helper CD4+ T into tumors while decreasing the percentage of M2 macrophages, MDSCs, and Tregs. Conclusion: Collectively, our findings revealed that CLEC11A could be a prognostic and immunological biomarker in GC, and CLEC11A-derived immune signature might serve as a new option for clinicians to predict outcomes and formulate personalized treatment plans for GC patients.

Molecular structure, expression, and functional role of Clec11a in skeletal biology and cancers

The role of Clec11a in bone construction and remodeling

C/Ebp Alpha Regulates Osteoclast Lineage Commitment

Clec11a/osteolectin is an osteogenic growth factor that promotes the maintenance of the adult skeleton

Integrin alpha11 is an Osteolectin receptor and is required for the maintenance of adult skeletal bone mass

High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia

Collectin-11 Promotes Cancer Cell Proliferation and Tumor Growth

CLEC18A interacts with sulfated GAGs and controls clear cell renal cell carcinoma progression

CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma

Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer

The molecular structure and role of CCL2 (MCP‐1) and C‐C chemokine receptor CCR2 in skeletal biology and diseases

Type-H endothelial cell protein Clec14a orchestrates osteoblast activity during trabecular bone formation and patterning

Claudin 11 regulates bone homeostasis via bidirectional EphB4-EphrinB2 signaling

Identification and characterization of CLEC11A and its derived immune signature in gastric cancer

Molecular cloning and characterization of a novel cystatin-like molecule, CLM, from human bone marrow stromal cells.

Protective effects of Clec11a in islets against lipotoxicity via modulation of proliferation and lipid metabolism in mice

CLEC11A methylation is correlated to AML subtypes and cytogenetic risk factors but not patient demographics

ALX1-transcribed LncRNA AC132217.4 Promotes Osteogenesis and Bone Healing Via IGF-AKT Signaling in Mesenchymal Stem Cells

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Structural and Functional Conservation of CLEC-2 with the Species-Specific Regulation of Transcript Expression in Evolution

CTHRC1, a novel gene with multiple functions in physiology, disease and solid tumors (Review)